What does the pharmaceutical sector generally refer to, and what are the individual stocks in the ph

The pharmaceutical sector is often mentioned, but there is no medicine...Maybe it's related to medicine, it's purely a concept? .Generally, it is OK to play "biopharmaceutical"...Medical devices, health care pharmaceuticals, Chinese patent medicines, etcMedical.

**There is a plate classification on the software.,The plates have**Details.。

Maybe it's related to medicine, it's purely a concept?

Medical devices and biopharmaceuticals.

Medical devices, health care pharmaceuticals, Chinese patent medicines, etc

Generally, it is OK to play "biopharmaceutical"...

The software border looks for industry classifications and opens medicine.

** Abbreviation: Gross Profit from Sales, Net Profit from Sales, Net Asset Revenue, Revenue per Share

Rate ( ) Name Rate ( ) Profit Rate ( ) Name (Yuan) Name

600216 Zhejiang Medicine 6 4 1 1

002001 Xinhecheng 3 1 2 2

002294 Salubris 2 2 4 3

600267 Hisun Pharmaceuticals 7 7 8 4

002399 Hepalink 8 3 5

600521 Huahai Pharmaceuticals 4 6 5 6

002332 Xianju Pharmaceuticals 5 9 6 7

002365 Yongan Pharmaceuticals 5 8

002020 Jingxin Pharmaceutical 9 9 9

000756 Xinhua Pharmaceutical

002411 nine nine long

000403 S*ST Biochem 1 8 3

000788 Southwest Synthesis 7

600789 Lukang Medicine

600488 Tianyao shares

000952 Guangji Pharmaceutical

600812 North China Pharmaceutical

600200 Wuzhong, Jiangsu

000739 Pulo shares

Compare with industry indicators

Huahai Pharmaceuticals 4 6 5 6

Industry average

The stock is relative to the average %.

Just part of it.

The leading companies in the pharmaceutical sector are: Sinopharm, Shanghai Pharmaceutical, Lukang Pharmaceutical, China Pharmaceutical, Wohua Pharmaceutical, etc.

Extended information] The pharmaceutical sector is not all drugs, and their real subdivisions include APIs, chemical preparations, biological preparations, medical services, medical devices, medical business and other fields. Therefore, when we speculate on related pharmaceutical stocks, we must observe the development of subdivided industries and select the one with a reversal in performance. All in all, the leading stocks in the pharmaceutical sector are often the ones with the most patents in the industry, because the threshold for this line is relatively high.

1.API industry: VE, VA leader Xinhecheng, VB5 leader Yifan Pharmaceutical, VB2 leader Guangji Pharmaceutical, VC leader North China Pharmaceutical, Northeast Pharmaceutical, etc., VD3 leader Garden Biology, antibiotic APA leader Federal Pharmaceutical, corticosteroid leader Xianju Pharmaceutical.

2.Chemical preparations: Hengrui Pharmaceutical, a leading tumor drug, Huahai Pharmaceutical, a leading sartempolil for hypertension, Sino Biopharmaceutical, a leading liver disease, Hepalink, a leading heparin, and Hanyu Pharmaceutical, a leading peptide.

3.Biological agents: the third-generation insulin leader Gan & Lee Pharmaceutical, the second-generation insulin leader Tonghua Dongbao, the blood product leader Hualan Biotechnology, the vaccine leader Kangtai Biology (this is controversial and needs to be subdivided), the monoclonal antibody leader Henlius and others (the monoclonal antibody is relatively scattered, and there are many enterprises in the layout, Hisun Biotechnology, Genor, etc.), the growth hormone leader Changchun High-tech, and the anti-allergic biological drug leader Wuwu Biotechnology.

4.Medical services: Aier Ophthalmology, Tongce Medical, a leading dental company, WuXi AppTec, a leading CRO company, Tigermed, a leading clinical CRO, WuXi Biologics, a leading bioCMO, Jinyu Medical, a leading independent laboratory, and Meinian Health, a leading medical examination business.

5.Medical devices: Mindray Medical, a leader in the medical device industry chain, Lepu Medical, a leader in cardiac stents, Wanfu Biotechnology, a leader in POCT, Yuyue Medical, a leader in household medical devices, Antu Biotechnology, a leader in chemiluminescence diagnostic reagents, and Jianfan Biotechnology, a leader in hemoperfusion equipment.

6.Pharmaceutical business: Yifeng Pharmacy, a leading pharmacy, and Sinopharm Holdings, a leading distributor.

There are two main reasons for the sharp decline in medical **:

First, the CDE issued a public solicitation on the "Guiding Principles for Clinical R&D of Clinical Value-Oriented Anti-tumor Drugs", proposing that "tumor R&D should be guided by clinical value", which was interpreted by the market as negative, resulting in a sharp decline in CRO concept stocks across the board;

Second, the pharmaceutical sector has risen significantly in the early stage, with more profits, and the recent overall market adjustment, dragged down by the sharp decline in the CRO concept, resulting in significant fluctuations in the entire sector today.

In the face of a number of pharmaceutical ** suffered heavy setbacks, first of all, we must avoid excessive staring. The original intention of us to buy ** is to let professionals help us invest, so we don't need to keep an eye on the market all the time and calculate our investment income every day. Since we hand it over to the manager, although the manager's ability has its own merits, we must also understand that "professional people do professional things", fully believe in their ability, and there is no need to pay too much attention to the ups and downs of **.

If you are in the mood of ups and downs every day, it is easy to lose yourself and forget the investment philosophy you adhere to. **After falling for three days in a row, I feel that I have entered the abyss of a bear market, and I hurriedly **cut the meat, and it is likely to give up long-term investment because of this. It's normal to stay on top of your earnings, but there's no need to stare at them with a magnifying glass, because investing is only a part of our lives, not the whole thing.